Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 755

A Novel Diagnostic Algorithm for Polymyalgia Rheumatica Using Three Musculoskeletal Sites on Whole Body PET/CT

9:00AM-11:00AM: Abstract Number: 756

A Volar Pattern of 18F-Fluorodeoxyglucose Uptake at the Hand on Whole Body PET/CT Predicts Glucocorticoid-Responsive Disease in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 768

Angiographic Patterns and Changes in Arterial Lesions in Patients with Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 765

Application of Different Sets of Classification/diagnostic Criteria for Polymyalgia Rheumatica: Single Center Study of 100 Patients

9:00AM-11:00AM: Abstract Number: 744

Are Hematologic Indexes Helpful in the Diagnosis and Prognosis of Polymyalgia Rheumatica?

9:00AM-11:00AM: Abstract Number: 762

Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study

9:00AM-11:00AM: Abstract Number: 743

Association Between Acute-phase Reactants, interleukin-6(IL6), Tumor Necrosis Factor-a(TNFa) and Disease Activity in Takayasu’s Arteritis During Follow-up with Repeated Evaluation of Vascular Imaging Manifestations

9:00AM-11:00AM: Abstract Number: 745

Cardiac Involvements Are Related to Poor Prognosis in Patients with Takayasu’s Arteritis in China

9:00AM-11:00AM: Abstract Number: 749

Childhood Takayasu Arteritis: Characteristics and Outcomes of a Mexican Cohort

9:00AM-11:00AM: Abstract Number: 746

Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK

9:00AM-11:00AM: Abstract Number: 769

Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up

9:00AM-11:00AM: Abstract Number: 747

Detrimental Factors Affecting the First-year Clinical Response in Korean Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 752

Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 754

Dynamic Distribution and Phenotype Shift from M1 to M2 of Macrophages in Vascular Lesions of Naïve and Treated Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 750

Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort

9:00AM-11:00AM: Abstract Number: 753

Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 758

Interleukin-6 May Predict Disease Relapse During Long-term Follow-up in Takayasu’s Arteritis in a Han Chinese Population

9:00AM-11:00AM: Abstract Number: 770

Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 757

Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 767

Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains

9:00AM-11:00AM: Abstract Number: 759

Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica?

9:00AM-11:00AM: Abstract Number: 742

Polymyalgia Rheumatica: New Therapeutic Strategy Based on Low Dose Metrotexate Plus Local Infiltration with Corticosteroids

9:00AM-11:00AM: Abstract Number: 761

Polymyalgia Rheumatica: Winter Is Coming

9:00AM-11:00AM: Abstract Number: 766

Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 751

Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group

9:00AM-11:00AM: Abstract Number: 760

Prescribing Methotrexate in Polymyalgia Rheumatica: A Missed Opportunity?

9:00AM-11:00AM: Abstract Number: 748

Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center

9:00AM-11:00AM: Abstract Number: 764

The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years

9:00AM-11:00AM: Abstract Number: 763

Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 741

Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu’s Arteritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].